Inactive Instrument

News Oxygen Biotherapeutics Inc Nasdaq

Equities

US69207P3082

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 14	Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Tenax Therapeutics: Q1 Earnings Snapshot	May. 14	AQ
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update	May. 14	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	Apr. 30	AQ
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	Apr. 09	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	Mar. 28	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics to Present at the 36th Annual Roth Conference	Mar. 12	AQ
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	Feb. 29	AQ
Tenax Therapeutics Secures Global Rights for Levosimendan	Feb. 20	MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	Feb. 20	CI
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	Feb. 20	AQ
Top Midday Decliners	Feb. 08	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	Feb. 08	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	Feb. 08	MT
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	Feb. 08	AQ
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	Feb. 08	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	Feb. 07	AQ
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	Feb. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oxygen Biotherapeutics Inc Nasdaq

Equities

US69207P3082

Summary

Filters